Thelansis

 GM2 gangliosidosis is a rare, inherited disorder that causes progressive damage to the nervous system. It is caused by a deficiency of the enzyme beta-hexosaminidase, which breaks down a type of fat called GM2 ganglioside. When GM2 ganglioside accumulates in cells, it damages neurons and other brain and spinal cord cells. GM2 gangliosidosis is divided into three clinical subtypes based on the age at onset: ·        Type 1 (Tay-Sachs disease) is the most common and severe form, with onset in the first few months of life. Children with type 1 GM2 gangliosidosis typically experience developmental delays, loss of motor skills, seizures, and vision and hearing loss. They usually die by the age of 4. ·        Type 2 (Sandhoff disease) is less common than type 1 and has a later onset, typically between the ages of 1 and 3. Children with type 2 GM2 gangliosidosis experience similar symptoms to those with type 1, but the progr...

 GM2 gangliosidosis is an autosomal recessive metabolic disorder due to β-hexosaminidase deficiency. GM2 gangliosidosis is divided into three clinical subtypes according to the age at onset. In general, the later the disease occurs, the more slowly it progresses. Type 1 (infantile type) begins in the first year of life with rapidly progressive diffuse neurological deterioration and death before four years of age. GM2 gangliosidosis is caused by deficiency of (beta-1,4 N-acetyl galactosaminidase) hexosaminidase activity. The two isoenzymes are called hexosaminidase A and B. Typical infantile forms of GM2 gangliosidosis are Tay–Sachs disease and Sandhoff disease. ·        The incidence of the Tay Sachs variant in the general population is estimated to be 1.75 cases per 250,000 live births. However, Sandhoff-variant incidence has been reported at 1 to 2 cases per 350,000 patients. ·        The most common initial symptoms...

GM2 Gangliosidosis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030 Description: Indication name: GM2 Gangliosidosis GM2 gangliosidosis is an autosomal recessive metabolic disorder due to β-hexosaminidase deficiency. GM2 gangliosidosis is divided into three clinical subtypes according to the age at onset. In general, the later the disease occurs, the more slowly it progresses. Type 1 (infantile type) begins in the first year of life with rapidly progressive diffuse neurological deterioration and death before 4 years of age. GM2 gangliosidosis is caused by deficiency of (beta-1,4 N-acetyl galactosaminidase) hexosaminidase activity. The two isoenzymes are called hexosaminidase A and B. Typical infantile forms of GM2 gangliosidosis are Tay–Sachs disease and Sandhoff disease. ·        The incidence of the Tay Sachs variant in the general population is estimated to be 1.75 cases per 250,000 live births, however, Sa...